Ben Shepherd
Co Founder & CEO @ Trestle Biotherapeutics
Known information
- Used to work at Organovo Holdings, Inc. as Vice President, Research and Preclinical Development in 2019 for 7 months
- Currently working at Trestle Biotherapeutics as Co-founder & CEO since 2020 for 4 years in San Diego, California, United States
- Used to work at Organovo Holdings, Inc. as Senior Director, Therapeutics, from 2018 to 2019 for 1 year in Greater San Diego Area
- Used to work at Yale University School of Medicine as Associate Research Scientist, from 2006 to 2009 for 3 years in New Haven, CT
- Used to work at Yale University School of Medicine as Postdoctoral Fellow, from 2003 to 2006 for 3 years in New Haven, CT
- Studied at University of Washington and studied Zoology and achieved B.S., from 1995 to 1999 for 4 years
- Studied at University of Arizona and studied Physiological Sciences and achieved PhD, from 1999 to 2003 for 4 years
- Oversaw preclinical translational research at Organovo
- Served as VP of Research & Preclinical Development at Organovo
- Earned a PhD from the University of Arizona in Physiological Sciences
- Helped guide and develop Organovo’s IP estate
- Named inventor on more than 10 patents
- Vascular biologist, tissue engineer, and regenerative medicine scientist by training
- Spent over 10 years leading R&D teams and business development efforts in the industry
- Author of more than 20 scientific articles and book chapters
- Received a BS in Zoology from the University of Washington
- Managed Organovo’s external academic collaborations
- Conducted postdoctoral training at the Yale School of Medicine
- Board certified cardiovascular perfusionist
- Led initial R&D efforts on 3D bioprinting for in vitro tissue models
About Trestle Biotherapeutics
Trestle Biotherapeutics, based in San Diego, develops implantable therapeutic tissues to aid patients with end-stage renal disease, aiming to reduce reliance on dialysis.